ATAI
ATAI Life Sciences N.V. (ATAI)
Healthcare • NASDAQ • $4.03+0.50%
- Symbol
- ATAI
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $4.03
- Daily Change
- +0.50%
- Market Cap
- $1.48B
- Trailing P/E
- N/A
- Forward P/E
- -8.05
- 52W High
- $6.75
- 52W Low
- $1.38
- Analyst Target
- $14.00
- Dividend Yield
- N/A
- Beta
- 1.60
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formul…
Company websiteResearch ATAI on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.